Correlation between annual change in health status and computer tomography derived lung density in subjects with α1-antitrypsin deficiency
暂无分享,去创建一个
H Putter | B C Stoel | J H C Reiber | H. Putter | B. Stoel | K. Rabe | J. Reiber | J. Stolk | J Stolk | W. Ng | M. E. Bakker | K F Rabe | M E Bakker | W H Ng | H. Putter | J. Reiber
[1] S. Spencer,et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease , 2003, Thorax.
[2] S. Spencer,et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study , 2003, Thorax.
[3] P M Calverley,et al. Health status deterioration in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.
[4] J. Roca,et al. Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.
[5] I. Pavord,et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial , 2000, The Lancet.
[6] R. Stockley,et al. Alpha-1-antitrypsin deficiency: what next? , 2000, Thorax.
[7] W. B. Hunt,et al. Pulmonary emphysema and alpha-1 antitrypsin deficiency. , 1972, Virginia medical monthly.
[8] F. Gleeson,et al. BTS guidelines for the management of pleural infection , 2003, Thorax.
[9] A. Miller,et al. Standardized lung function testing. , 1984, Bulletin europeen de physiopathologie respiratoire.
[10] M Thomas,et al. Breathing exercises and asthma , 2003, Thorax.
[11] H A Vrooman,et al. Sources of error in lung densitometry with CT. , 1999, Investigative radiology.
[12] J. C. Caminero Luna. [Pleural tuberculosis]. , 1990, Medicina clinica.
[13] J E Earis,et al. The inspiratory "squawk" in extrinsic allergic alveolitis and other pulmonary fibroses. , 1982, Thorax.
[14] A. Vyshedskiy,et al. Sound transmission in the lung as a function of lung volume. , 2002, Journal of applied physiology.
[15] R. Stockley,et al. Longitudinal changes in physiological, radiological, and health status measurements in alpha(1)-antitrypsin deficiency and factors associated with decline. , 2001, American journal of respiratory and critical care medicine.
[16] P De Vuyst,et al. Comparison of computed density and macroscopic morphometry in pulmonary emphysema. , 1995, American journal of respiratory and critical care medicine.
[17] J. Best,et al. CT measurements of lung density in life can quantitate distal airspace enlargement--an essential defining feature of human emphysema. , 1988, The American review of respiratory disease.
[18] J. Roca,et al. Standardization of the measurement of transfer factor (diffusing capacity) , 1993, European Respiratory Journal.
[19] M. Jacobs,et al. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin , 1994, Antimicrobial Agents and Chemotherapy.
[20] A. Tattersfield,et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial , 2003, Thorax.
[21] P. Jones,et al. Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.
[22] P. Jones. Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.
[23] S. Spencer,et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.
[24] P. Jones,et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.
[25] P. Jones,et al. The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.
[26] W. F. Miller,et al. Pulmonary emphysema and alpha 1-antitrypsin deficiency. , 1968, The American journal of medicine.
[27] E. Piitulainen,et al. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). , 1999, The European respiratory journal.
[28] R. Peto,et al. The natural history of chronic airflow obstruction. , 1977, British medical journal.
[29] H A Vrooman,et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. , 1999, American journal of respiratory and critical care medicine.
[30] J E Cotes,et al. Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.
[31] P. D. Oldham,et al. A note on the analysis of repeated measurements of the same subjects. , 1962, Journal of chronic diseases.
[32] E. Ernst. Complementary therapies for asthma: what patients use. , 1998, The Journal of asthma : official journal of the Association for the Care of Asthma.
[33] M. Pearson. Guidelines for the management of chronic obstructive pulmonary disease. , 1999, Caribbean health.
[34] S. Eriksson,et al. PULMONARY EMPHYSEMA AND ALPHA1-ANTITRYPSIN DEFICIENCY. , 2009, Acta medica Scandinavica.
[35] M. Partridge,et al. The use of complementary medicines by those with asthma. , 2003, Respiratory medicine.
[36] I. Pavord,et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.